deferoxamine has been researched along with Kidney Failure, Chronic in 135 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Improvement of microcytic anemia after deferoxamine treatment is described in eight long-term dialysis patients with high serum aluminum concentration and other clinical signs of aluminum toxicity." | 7.67 | Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. ( Burnatowska-Hledin, M; Dombrouski, J; Mayor, G; Swartz, R, 1987) |
| "Insulin resistance is associated with increased cardiovascular diseases." | 5.40 | Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. ( Alnahal, AA; Fathy, A; Fathy, T; Tahan, M, 2014) |
| "Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 5.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
| "Three haemodialyzed chronic renal failure patients with histologically proven osteomalacia due to aluminium toxicity were treated with repeated injections of desferrioxamine, a potent chelator of aluminium." | 5.27 | [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning]. ( Accominotti, M; Chapuy, MC; Charhon, SA; Chavassieux, P; Meunier, PJ; Traeger, J, 1986) |
| "Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)." | 5.27 | Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988) |
| "We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate." | 3.67 | Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. ( Corwin, HL; Mayor, GH; Sprague, SM; Tanner, CM; Wilson, RS, 1986) |
| "Improvement of microcytic anemia after deferoxamine treatment is described in eight long-term dialysis patients with high serum aluminum concentration and other clinical signs of aluminum toxicity." | 3.67 | Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. ( Burnatowska-Hledin, M; Dombrouski, J; Mayor, G; Swartz, R, 1987) |
| "Desferrioxamine (DFO) was administered intravenously to a 63-year-old chronic hemodialysis patient with osteomalacia believed secondary to aluminum intoxication." | 3.67 | Thrombocytopenia associated with intravenous desferrioxamine. ( Eisinger, RP; Sherman, RA; Walker, JA, 1985) |
| " It is recommended to implement a stepwise increasing desferrioxamine dosage to prevent an acute decompensation with irreversible neurological lesions." | 2.58 | [Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature]. ( Canaud, B; Dard, S; Drueke, T; Dupuis, E; Massy, ZA; Seidowsky, A, 2018) |
| "Renal osteodystrophy is multifactorial." | 2.38 | Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients. ( Tzamaloukas, AH, 1990) |
| " This substance is well absorbed orally and has been shown to enhance the excretion of ferric ion in iron loaded rats." | 2.36 | [Iron chelation. Biological significance and medical application]. ( Peter, HH, 1983) |
| "Insulin resistance is associated with increased cardiovascular diseases." | 1.40 | Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. ( Alnahal, AA; Fathy, A; Fathy, T; Tahan, M, 2014) |
| "Changes in aluminum, TFS and r-HuEPO dosage were unremarkable (p > 0." | 1.30 | Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects. ( Chen, JB; Hsu, KT; Lam, KK; Lee, CT; Liao, SC, 1999) |
| "The deferoxamine test was performed as a diagnostic tool for aluminum intoxication." | 1.29 | Influence of iron status in the response to the deferoxamine test. ( Acuña, G; Alonso, M; Alvarez-Grande, J; Cannata, JB; Caramelo, C; Díaz-López, B; Fernández-Martín, JL; Olaizola, I, 1996) |
| " In this paper we studied the eventually adverse otologic effects of DFO in 20 patients receiving haemodialysis." | 1.28 | [Ototoxicity of deferoxamine]. ( Biurrun, O; de España, R; Lorente, J; Orteu, N; Traserra, J; Valls, J, 1992) |
| " The biochemical evidence of functional iron deficiency and the response to aluminum chelation therapy support the hypothesis that the inhibitory effect of aluminum on erythropoiesis is mediated by the interference of aluminum with the bioavailability of iron." | 1.28 | The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment. ( Donnelly, SM; Smith, EK, 1990) |
| " Ocular, auditory, and infectious adverse effects have occurred with the use of deferoxamine." | 1.28 | Deferoxamine for aluminum toxicity in dialysis patients. ( Hernandez, P; Johnson, CA, 1990) |
| "In the undialyzed patient with chronic renal failure, the concentrations of silicon in plasma increased with decreasing glomerular filtration rate." | 1.28 | Silicon measurement in serum and urine by direct current plasma emission spectrometry. ( Roberts, NB; Williams, P, 1990) |
| "The 11 patients with chronic renal failure had the operation of the internal A-V shunt." | 1.28 | [Evaluation of thrombus scintigraphy using 67Ga-deferoxamine-dialdehydestarch-fibrinogen in patients with internal A-V shunt]. ( Hachiya, Y; Hirata, K; Iida, M; Kawamura, Y; Matsuzaki, K; Morishita, T; Noguchi, M; Obara, T; Uchi, T; Yamazaki, J, 1990) |
| "Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 1.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
| "In 10 children with chronic renal failure, there was a linear correlation (r = 0." | 1.28 | Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD. ( Andreoli, SP; Cohen, M, 1989) |
| "Deferoxamine is a chelating agent used in the treatment of transfusional iron overload and more recently in the diagnosis and treatment of increased aluminum body stores in chronic renal failure patients." | 1.28 | Irreversible ocular toxicity from single "challenge" dose of deferoxamine. ( Bene, C; Bene, D; Kranias, G; Manzler, A, 1989) |
| " Quantitative data regarding optimal dosage and application of DFO in RDT patients are not yet available." | 1.27 | Therapy and monitoring of hypersiderosis in chronic renal insufficiency. ( Baldamus, CA; Bechstein, PB; Fassbinder, W; Hilfenhaus, M; Koch, KM; Schmidt, H, 1984) |
| "Three haemodialyzed chronic renal failure patients with histologically proven osteomalacia due to aluminium toxicity were treated with repeated injections of desferrioxamine, a potent chelator of aluminium." | 1.27 | [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning]. ( Accominotti, M; Chapuy, MC; Charhon, SA; Chavassieux, P; Meunier, PJ; Traeger, J, 1986) |
| "Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)." | 1.27 | Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988) |
| " During the interdialysis period, there was a decrease of plasma desferrioxamine concentrations with a mean half-life of 18." | 1.27 | Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. ( Allain, P; Ang, KS; Beaudeau, G; Cam, G; Chaleil, D; Ciancioni, C; Mauras, Y; Poignet, JL; Simon, P; Varin, MC, 1987) |
| "0." | 1.27 | Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. ( Schaefer, K; Seifert, A; von Herrath, D, 1987) |
| " Using reversed osmosis in dialysis the high aluminium levels in bone result mainly from the long-term use of phosphate binders." | 1.27 | [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure]. ( Beck, G; Gmeiner, R; König, P; Lechleitner, P, 1987) |
| " We conclude, that DFO in a dosage of 30 mg/kg body weight given at the end of HD is able to remove more than 500 mg iron/month if it is administered following each HD." | 1.27 | Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results. ( Graf, H; Irschik, H; Kovarik, J; Linkesch, W; Meisinger, V; Stummvoll, HK; Woloszczuk, W, 1985) |
| "Hemosiderosis was noted in 16 MHD patients (group II) and correlated with iron load." | 1.26 | [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)]. ( Bonn, F; Guezennec, M; Simon, P; Tanquerel, T, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 70 (51.85) | 18.7374 |
| 1990's | 57 (42.22) | 18.2507 |
| 2000's | 4 (2.96) | 29.6817 |
| 2010's | 4 (2.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seidowsky, A | 1 |
| Dupuis, E | 1 |
| Drueke, T | 1 |
| Dard, S | 1 |
| Massy, ZA | 1 |
| Canaud, B | 1 |
| Alnahal, AA | 1 |
| Tahan, M | 1 |
| Fathy, A | 1 |
| Fathy, T | 1 |
| Labidi, J | 1 |
| Pepper, R | 1 |
| Campbell, N | 1 |
| Yaqoob, MM | 1 |
| Roberts, NB | 3 |
| Fan, SL | 1 |
| London, GM | 1 |
| Marty, C | 1 |
| Marchais, SJ | 1 |
| Guerin, AP | 1 |
| Metivier, F | 1 |
| de Vernejoul, MC | 1 |
| Sikole, A | 1 |
| Stojkovski, L | 1 |
| Cakalaroski, K | 1 |
| Stojcev, N | 1 |
| Amitov, V | 1 |
| Polenakovic, M | 1 |
| Brown, DJ | 1 |
| Dawborn, JK | 1 |
| Ham, KN | 1 |
| Xipell, JM | 1 |
| Chang, TM | 1 |
| Barre, P | 1 |
| Peter, HH | 1 |
| Ihle, BU | 2 |
| Buchanan, MR | 1 |
| Stevens, B | 1 |
| Becker, GJ | 2 |
| Kincaid-Smith, P | 1 |
| Malluche, HH | 2 |
| Smith, AJ | 2 |
| Abreo, K | 1 |
| Faugere, MC | 2 |
| Pierides, AM | 1 |
| Myli, MP | 1 |
| Ciancioni, C | 3 |
| Poignet, JL | 3 |
| Mauras, Y | 5 |
| Panthier, G | 1 |
| Delons, S | 2 |
| Allain, P | 5 |
| Man, NK | 2 |
| Falk, RJ | 1 |
| Mattern, WD | 1 |
| Lamanna, RW | 1 |
| Gitelman, HJ | 1 |
| Parker, NC | 1 |
| Cross, RE | 1 |
| Rastall, JR | 1 |
| Culpepper, CP | 1 |
| Cummings, R | 1 |
| Westervelt, FB | 1 |
| Savory, J | 2 |
| Wills, MR | 1 |
| Hilfenhaus, M | 1 |
| Koch, KM | 1 |
| Bechstein, PB | 1 |
| Schmidt, H | 1 |
| Fassbinder, W | 1 |
| Baldamus, CA | 1 |
| Ackrill, P | 7 |
| Day, JP | 8 |
| Garstang, FM | 2 |
| Hodge, KC | 1 |
| Metcalfe, PJ | 2 |
| Benzo, Z | 1 |
| Hill, K | 1 |
| Ralston, AJ | 2 |
| Ball, J | 1 |
| Denton, J | 1 |
| Simon, P | 6 |
| Bonn, F | 1 |
| Guezennec, M | 1 |
| Tanquerel, T | 1 |
| Graf, H | 2 |
| Stummvoll, HK | 2 |
| Meisinger, V | 2 |
| Ceriati, F | 1 |
| Cavicchioni, C | 1 |
| Marino, IR | 1 |
| Pomponi, M | 1 |
| Nankivell, BJ | 1 |
| Chen, J | 1 |
| Boadle, RA | 1 |
| Harris, DC | 1 |
| Cronin, RE | 1 |
| Głuszek, J | 1 |
| Adamczak, H | 1 |
| Davie, MW | 1 |
| Worsfold, M | 1 |
| Sharp, CA | 1 |
| Perks, J | 1 |
| Yokel, RA | 1 |
| Olivero, JJ | 1 |
| Yaqoob, M | 1 |
| Ahmad, R | 2 |
| McClelland, P | 1 |
| Shivakumar, KA | 1 |
| Sallomi, DF | 1 |
| Fahal, IH | 1 |
| Helliwell, T | 1 |
| Gerakis, A | 1 |
| Apostolou, T | 1 |
| Billis, A | 1 |
| Anthone, S | 1 |
| Ambrus, CM | 1 |
| Kohli, R | 1 |
| Min, I | 1 |
| Anthone, R | 1 |
| Stadler, A | 1 |
| Stadler, I | 1 |
| Vladutiu, A | 1 |
| Barata, JD | 1 |
| D'Haese, PC | 3 |
| Pires, C | 1 |
| Lamberts, LV | 2 |
| Simões, J | 1 |
| De Broe, ME | 3 |
| Andriani, M | 1 |
| Nordio, M | 1 |
| Saporiti, E | 1 |
| Cannata, JB | 1 |
| Fernández-Martín, JL | 1 |
| Díaz-López, B | 1 |
| Alonso, M | 1 |
| Olaizola, I | 1 |
| Acuña, G | 1 |
| Caramelo, C | 1 |
| Alvarez-Grande, J | 1 |
| Cannata Andía, JB | 1 |
| Romero, RA | 3 |
| Salgado, O | 3 |
| Rodríguez-Iturbe, B | 3 |
| Tahán, JE | 2 |
| Elejalde, LE | 1 |
| Klemm, A | 1 |
| Sperschneider, H | 1 |
| Winnefeld, K | 1 |
| Günther, K | 1 |
| Stein, G | 1 |
| Kalinowski, M | 1 |
| Popławski, A | 1 |
| Kaliszewski, Z | 1 |
| Juzwiuk, J | 1 |
| Aucella, F | 2 |
| Vigilante, M | 2 |
| Scalzulli, P | 2 |
| Musto, P | 2 |
| Crisetti, A | 1 |
| Modoni, S | 1 |
| Carotenuto, M | 2 |
| Stallone, C | 2 |
| Nicholas, JC | 1 |
| Dawes, PT | 1 |
| Davies, SJ | 1 |
| Freemont, AJ | 1 |
| Prencipe, M | 1 |
| Valente, GL | 1 |
| Lee, CT | 1 |
| Liao, SC | 1 |
| Hsu, KT | 1 |
| Lam, KK | 1 |
| Chen, JB | 1 |
| Norman, JT | 1 |
| Clark, IM | 1 |
| Garcia, PL | 1 |
| Espósito, BP | 1 |
| Breuer, W | 1 |
| Slotki, I | 1 |
| Cabantchik, ZI | 1 |
| Vreugdenhil, G | 1 |
| Feelders, RA | 1 |
| Coppens, PJ | 1 |
| de Leeuw, PW | 1 |
| DeVita, MV | 1 |
| Rasenas, LL | 1 |
| Bansal, M | 1 |
| Gleim, GW | 1 |
| Zabetakis, PM | 1 |
| Gardenswartz, MH | 1 |
| Michelis, MF | 1 |
| Nakazawa, R | 1 |
| Ogura, Y | 1 |
| Yokoyama, K | 1 |
| Ohara, M | 1 |
| Kurihara, S | 1 |
| Marumo, F | 1 |
| Vasilakakis, DM | 1 |
| Lemoniatou, E | 1 |
| Digenis, PN | 1 |
| Min, DI | 1 |
| D'Elia, JA | 1 |
| de España, R | 1 |
| Biurrun, O | 1 |
| Lorente, J | 1 |
| Valls, J | 1 |
| Orteu, N | 1 |
| Traserra, J | 1 |
| Verbeelen, D | 2 |
| Gaughan, WJ | 1 |
| Beserab, A | 1 |
| Stein, HD | 1 |
| Sirota, RA | 1 |
| Yudis, M | 1 |
| Haug, BA | 1 |
| Botsch, G | 1 |
| Felgenhauer, K | 1 |
| Hoen, B | 1 |
| Kessler, M | 1 |
| Cabanne, JF | 1 |
| Dubot, P | 1 |
| Navarro, JA | 1 |
| Granadillo, VA | 1 |
| García, R | 1 |
| Subra, JF | 1 |
| Krari, N | 1 |
| Tirot, P | 1 |
| Balit, G | 1 |
| Van-Weydevelt, FC | 1 |
| de la Serna, FJ | 1 |
| Gilsanz, F | 1 |
| Praga, M | 2 |
| Estenoz, J | 2 |
| Válek, A | 1 |
| Sulková, S | 1 |
| Laurinová, Z | 1 |
| Lowrey, S | 1 |
| Ponz, E | 1 |
| Campistol, JM | 3 |
| Ribalta, T | 1 |
| Montoliú, J | 2 |
| Ramírez, J | 1 |
| Almirall, J | 1 |
| Revert, L | 3 |
| von Bonsdorff, M | 1 |
| Sipilä, R | 1 |
| Pitkänen, E | 1 |
| Umeda, M | 1 |
| Tsurusaki, K | 1 |
| Kamikawa, S | 1 |
| Izumi, N | 1 |
| Yasumoto, R | 1 |
| Kishimoto, T | 1 |
| Maekawa, M | 1 |
| Roxe, DM | 1 |
| Krumlovsky, FA | 1 |
| Del Greco, F | 1 |
| Fitzsimons, E | 1 |
| Tzamaloukas, AH | 1 |
| Andreoli, SP | 3 |
| Chesney, RW | 1 |
| Salusky, IB | 2 |
| Sedman, AB | 2 |
| Donnelly, SM | 1 |
| Smith, EK | 1 |
| Brown, SJ | 1 |
| Slizofski, WJ | 1 |
| Dadparvar, S | 1 |
| Coburn, JW | 7 |
| Nelson, P | 1 |
| Goodman, WG | 1 |
| Hernandez, P | 1 |
| Johnson, CA | 1 |
| Ellenberg, R | 1 |
| King, AL | 1 |
| Sica, DA | 1 |
| Posner, M | 1 |
| Williams, P | 1 |
| Hosokawa, S | 1 |
| Oyamaguchi, A | 1 |
| Yoshida, O | 1 |
| Yamazaki, J | 1 |
| Uchi, T | 1 |
| Kawamura, Y | 1 |
| Iida, M | 1 |
| Hachiya, Y | 1 |
| Matsuzaki, K | 1 |
| Morishita, T | 1 |
| Obara, T | 1 |
| Hirata, K | 1 |
| Noguchi, M | 1 |
| Andress, DL | 3 |
| Nebeker, HG | 4 |
| Ott, SM | 3 |
| Endres, DB | 1 |
| Alfrey, AC | 3 |
| Slatopolsky, EA | 2 |
| Sherrard, DJ | 6 |
| Lillevang, ST | 1 |
| Pedersen, FB | 1 |
| Bia, MJ | 1 |
| Cooper, K | 1 |
| Schnall, S | 1 |
| Duffy, T | 1 |
| Hendler, E | 1 |
| Malluche, H | 1 |
| Solomon, L | 1 |
| Nakamura, M | 1 |
| Weil, WB | 1 |
| Kaufman, DB | 1 |
| Chazan, JA | 1 |
| Abuelo, JG | 1 |
| Blonsky, SL | 1 |
| Van Wyck, DB | 1 |
| Stivelman, JC | 1 |
| Ruiz, J | 1 |
| Kirlin, LF | 1 |
| Katz, MA | 1 |
| Ogden, DA | 1 |
| Arizono, K | 1 |
| Fukui, H | 1 |
| Miura, H | 1 |
| Hayano, K | 1 |
| Otsuka, Y | 1 |
| Tajiri, M | 1 |
| Cohen, M | 1 |
| Felsenfeld, AJ | 1 |
| Rodriguez, M | 1 |
| Coleman, M | 1 |
| Ross, D | 1 |
| Llach, F | 2 |
| Bene, C | 1 |
| Manzler, A | 1 |
| Bene, D | 1 |
| Kranias, G | 1 |
| Tielemans, C | 1 |
| Boelaert, J | 1 |
| Vergauwe, P | 1 |
| van Roost, G | 1 |
| Segaert, M | 1 |
| van Frachen, B | 1 |
| Lenclud, C | 1 |
| Charhon, SA | 1 |
| Chavassieux, P | 1 |
| Chapuy, MC | 1 |
| Accominotti, M | 1 |
| Traeger, J | 1 |
| Meunier, PJ | 1 |
| Smeyers-Verbeke, J | 1 |
| van Hooff, I | 1 |
| de Roy, G | 1 |
| Norris, KC | 2 |
| Andrés, A | 1 |
| de la Serna, J | 1 |
| Ruilope, LM | 1 |
| Nieto, J | 1 |
| Millet, VG | 1 |
| Arnaiz, F | 1 |
| Rodicio, JL | 1 |
| Davenport, A | 1 |
| Boyce, BF | 1 |
| Mocan, MZ | 1 |
| Byars, J | 1 |
| Junor, BJ | 1 |
| Mathys, B | 1 |
| Baeck, A | 1 |
| Verougstraete, C | 1 |
| Verstappen, A | 1 |
| D'Haene, M | 1 |
| Zanen, A | 1 |
| Boelaert, JR | 1 |
| van Roost, GF | 1 |
| Vergauwe, PL | 1 |
| Verbanck, JJ | 1 |
| de Vroey, C | 1 |
| Segaert, MF | 1 |
| Massry, SG | 1 |
| Cases, A | 2 |
| Sabater, M | 1 |
| López-Pedret, J | 1 |
| Kelly, J | 1 |
| Sabater, J | 1 |
| Torras, A | 1 |
| López, I | 1 |
| Chaleil, D | 2 |
| Varin, MC | 2 |
| Ang, KS | 3 |
| Cam, G | 3 |
| Walker, JV | 1 |
| Boykin, JL | 1 |
| Bia, M | 1 |
| Slatopolsky, E | 1 |
| Beaudeau, G | 1 |
| Seifert, A | 1 |
| von Herrath, D | 1 |
| Schaefer, K | 1 |
| Milliner, DS | 3 |
| Hercz, G | 1 |
| Miller, JH | 1 |
| Shinaberger, JH | 1 |
| Nissenson, AR | 1 |
| Maloney, NA | 1 |
| Friedler, RM | 1 |
| Kincaid-Smith, PS | 1 |
| Santos, F | 1 |
| Massie, MD | 1 |
| Chan, JC | 1 |
| Bournerias, F | 1 |
| Monnier, N | 1 |
| Dufier, JL | 1 |
| Réveillaud, RJ | 1 |
| Roodhooft, AM | 1 |
| van de Vyver, FL | 1 |
| van Acker, KJ | 1 |
| Visser, WJ | 1 |
| O'Brien, AA | 1 |
| Moore, DP | 1 |
| Keogh, JA | 1 |
| Lechleitner, P | 1 |
| Gmeiner, R | 1 |
| Beck, G | 1 |
| König, P | 1 |
| Hughes, H | 1 |
| Hagen, LE | 1 |
| Cameron, EC | 1 |
| Sutton, RA | 1 |
| Warady, BA | 1 |
| Ford, DM | 1 |
| Gaston, CE | 1 |
| Huffer, WE | 1 |
| Lum, GM | 1 |
| Sprague, SM | 1 |
| Corwin, HL | 1 |
| Wilson, RS | 1 |
| Mayor, GH | 1 |
| Tanner, CM | 1 |
| Hewitt, CD | 1 |
| O'Hara, M | 1 |
| Bourdon, S | 1 |
| Houzé, P | 1 |
| Bourdon, R | 1 |
| Swartz, R | 1 |
| Dombrouski, J | 1 |
| Burnatowska-Hledin, M | 1 |
| Mayor, G | 1 |
| Kovarik, J | 1 |
| Irschik, H | 1 |
| Woloszczuk, W | 1 |
| Linkesch, W | 1 |
| Monge, MF | 1 |
| Mikol, F | 1 |
| Naret, C | 1 |
| Dunn, D | 1 |
| DeMyer, W | 1 |
| Bergstein, JM | 1 |
| McCarthy, JT | 1 |
| Kurtz, SB | 1 |
| McCall, JT | 1 |
| Weiland, P | 1 |
| Köhler, M | 1 |
| Glatzel, E | 1 |
| Walker, JA | 1 |
| Sherman, RA | 1 |
| Eisinger, RP | 1 |
| Kramer, P | 1 |
| Hauswaldt, C | 1 |
| Lankisch, PG | 1 |
| Schrader, C | 1 |
| Otten, E | 1 |
| Köthe, E | 1 |
| Scheler, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients[NCT01011699] | Phase 3 | 176 participants (Actual) | Interventional | 2010-01-31 | Terminated (stopped due to Financial problem) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for deferoxamine and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature].
Topics: Aluminum; Brain Diseases; Deferoxamine; Electrocardiography; Humans; Kidney Failure, Chronic; Male; | 2018 |
[Iron chelation. Biological significance and medical application].
Topics: Animals; Bacterial Infections; Catechols; Deferoxamine; Diabetes Mellitus; Enterobactin; Female; Hum | 1983 |
The chemistry of desferrioxamine chelation for aluminum overload in renal dialysis patients.
Topics: Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Renal Dialysis | 1993 |
Southwestern Internal Medicine Conference: bone disease in kidney failure: diagnosis and management.
Topics: Aged; Biopsy; Bone and Bones; Bone Diseases; Calcitriol; Calcium; Chelating Agents; Chronic Kidney D | 1993 |
[Aluminum in chronic renal failure].
Topics: Aluminum; Bone and Bones; Deferoxamine; Humans; Kidney Failure, Chronic; Renal Dialysis; Skin | 1993 |
Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
Topics: Adult; Aluminum; Animals; Carboxylic Acids; Chelating Agents; Chelation Therapy; Child; Deferoxamine | 1994 |
Diagnosis and treatment of aluminium overload in end-stage renal failure patients.
Topics: Aluminum; Deferoxamine; Dialysis Solutions; Humans; Kidney Failure, Chronic; Renal Dialysis | 1993 |
Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Consensus conference. Paris, France, 27 June 1992.
Topics: Aluminum; Deferoxamine; Dialysis Solutions; Humans; Kidney Failure, Chronic; Renal Dialysis | 1993 |
The use of desferrioximine in dialysis-associated aluminium disease.
Topics: Aluminum; Anemia; Bone Diseases; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Rena | 1993 |
Aluminium toxicity: its relationship with bone and iron metabolism.
Topics: Aluminum; Bone and Bones; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failure, Chronic; Parat | 1996 |
[Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
Topics: Deferoxamine; Female; Humans; Kidney Failure, Chronic; Middle Aged; Mucormycosis; Renal Dialysis | 1991 |
Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
Topics: Aluminum; Biopsy; Bone and Bones; Bone Diseases; Calcitriol; Chronic Kidney Disease-Mineral and Bone | 1990 |
Osteomalacia and bone disease arising from aluminum.
Topics: Aluminum; Animals; Bone and Bones; Bone Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Ost | 1986 |
The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
Topics: Adult; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Renal | 1988 |
Prevention and treatment of the abnormalities in divalent ion metabolism in renal failure.
Topics: Aluminum; Calcium Metabolism Disorders; Deferoxamine; Humans; Kidney Failure, Chronic; Parathyroid G | 1986 |
Risk factors in aluminum toxicity in children with chronic renal failure.
Topics: Acidosis; Adolescent; Adult; Aluminum; Aluminum Hydroxide; Bone and Bones; Child; Citrates; Citric A | 1986 |
Detoxification in hemosiderosis.
Topics: Administration, Oral; Adult; Aluminum; Deferoxamine; Hemosiderosis; Humans; Injections, Intravenous; | 1985 |
Prevention and treatment of aluminum intoxication in chronic renal failure.
Topics: Aged; Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Kinetics; Middle Aged; Perito | 1985 |
9 trials available for deferoxamine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Do oral aluminium phosphate binders cause accumulation of aluminium to toxic levels?
Topics: Administration, Oral; Aluminum; Aluminum Compounds; Deferoxamine; Dialysis Solutions; Humans; Hyperp | 2011 |
Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.
Topics: Adsorption; Aluminum; Charcoal; Clinical Trials as Topic; Deferoxamine; Hemoperfusion; Humans; Iron; | 1983 |
Treatment of aluminum overload using a cartridge with immobilized desferrioxamine.
Topics: Aluminum; Chromatography, Gel; Deferoxamine; Extracorporeal Circulation; Humans; Kidney Failure, Chr | 1995 |
Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Topics: Adult; Aged; Aged, 80 and over; Aluminum; Antidotes; Deferoxamine; Dose-Response Relationship, Drug; | 1996 |
Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients.
Topics: Aged; Aged, 80 and over; Cell Division; Deferoxamine; Erythroid Precursor Cells; Female; Humans; Int | 1998 |
Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Carbohydrates; Chemistry, Pharmaceutical; Cohort | 2002 |
Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
Topics: Adult; Aluminum; Charcoal; Deferoxamine; Female; Ferric Compounds; Hemoperfusion; Humans; Kidney Fai | 1992 |
[Infectious risks in patients with renal failure on hemodialysis. Importance of iron overload and deferoxamine].
Topics: Bacterial Infections; Deferoxamine; Ferritins; Humans; Incidence; Iron; Kidney Failure, Chronic; Lis | 1991 |
Clearance of aluminum by hemodialysis: effect of desferrioxamine.
Topics: Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Osteomalacia; Renal Dialysis | 1986 |
108 other studies available for deferoxamine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Carotid Intima-Media Thic | 2014 |
Porphyria cutanea tarda in a chronic hemodialysis patient.
Topics: Adult; Biomarkers; Biopsy; Deferoxamine; Female; Ferritins; Fluorescent Antibody Technique; Hemoglob | 2010 |
Arterial calcifications and bone histomorphometry in end-stage renal disease.
Topics: Aluminum; Bicarbonates; Bone and Bones; Bone Density; Calcium; Calcium Phosphates; Chronic Kidney Di | 2004 |
Successful treatment of soft tissue calcifications in uremia.
Topics: Buttocks; Calcinosis; Deferoxamine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Kidne | 2006 |
Treatment of dialysis osteomalacia with desferrioxamine.
Topics: Adult; Alkaline Phosphatase; Aluminum; Bone and Bones; Calcium; Deferoxamine; Electron Probe Microan | 1982 |
The efficacy of various treatment modalities on aluminium associated bone disease.
Topics: Adult; Alkaline Phosphatase; Aluminum; Bone and Bones; Bone Diseases; Deferoxamine; Humans; Kidney F | 1983 |
The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure.
Topics: Adult; Aluminum; Bone and Bones; Child, Preschool; Deferoxamine; Female; Humans; Infusions, Parenter | 1984 |
Therapy of aluminum overload (I).
Topics: Adult; Aged; Aluminum; Bone and Bones; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, | 1984 |
Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
Topics: Adult; Aluminum; Deferoxamine; Female; Humans; Infusions, Parenteral; Iron; Kidney Failure, Chronic; | 1984 |
Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine.
Topics: Adult; Anemia, Sickle Cell; Deferoxamine; Female; Humans; Injections, Intravenous; Iron; Kidney Fail | 1983 |
Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
Topics: Aged; Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; | 1983 |
Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
Topics: Aluminum; Anemia, Hypochromic; Blood; Blood Transfusion; Combined Modality Therapy; Deferoxamine; He | 1984 |
Therapy of aluminium overload (II).
Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Osteomalacia; Renal Dialysi | 1984 |
Treatment of fracturing renal osteodystrophy by desferrioxamine.
Topics: Adult; Aged; Aluminum; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamin | 1983 |
[Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
Topics: Adult; Aged; Biopsy, Needle; Deferoxamine; Female; Ferritins; Hemochromatosis; Hemosiderosis; Hepati | 1981 |
Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
Topics: Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Kinetics; Renal Dialysis | 1981 |
[Deferoxamine B treatment of hemosiderosis in the anephric patient undergoing hemodialysis].
Topics: Adult; Deferoxamine; Hemosiderosis; Humans; Kidney Failure, Chronic; Male; Renal Dialysis | 1981 |
The role of tubular iron accumulation in the remnant kidney.
Topics: Animals; Creatinine; Deferoxamine; Disease Models, Animal; Electron Probe Microanalysis; Ferric Comp | 1994 |
Anomalous rise of serum osteocalcin following desferrioxamine treatment in aluminium intoxication.
Topics: Aluminum; Bone Development; Calcification, Physiologic; Chromatography, Gel; Deferoxamine; Female; H | 1993 |
Hemoptysis and altered sensorium in a hemodialysis patient.
Topics: Aluminum; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Hemoptysis; Humans; Kidney Failure, Chro | 1993 |
Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
Topics: Aluminum; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Humans; Kidney Failure, Chronic; Mi | 1993 |
Release of osteocalcin fragments in the serum of dialyzed patients during desferrioxamine treatment.
Topics: Antidotes; Combined Modality Therapy; Deferoxamine; Humans; Kidney Failure, Chronic; Osteocalcin; Re | 1995 |
Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
Topics: Aluminum; Antidotes; Chelating Agents; Data Interpretation, Statistical; Deferoxamine; Drug Administ | 1996 |
Influence of iron status in the response to the deferoxamine test.
Topics: Aluminum; Antidotes; Deferoxamine; Humans; Iron; Kidney Failure, Chronic; Retrospective Studies; Tra | 1996 |
Bone metal mobilization induced by long-term desferrioxamine B therapy in continuous ambulatory peritoneal dialysis.
Topics: Adult; Bone and Bones; Calcification, Physiologic; Deferoxamine; Humans; Kidney Failure, Chronic; Ma | 1996 |
Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
Topics: Adult; Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Metals; Osteomalacia; Peritone | 1996 |
Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
Topics: Aluminum; Biocompatible Materials; Deferoxamine; Female; Hemofiltration; Humans; Kidney Failure, Chr | 1997 |
[Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
Topics: Adult; Aluminum; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Humans; Iron; Kidney Failure, | 1996 |
Persisting aluminium-related bone disease after cadaveric renal transplantation.
Topics: Aluminum Hydroxide; Biopsy; Bone and Bones; Bone Diseases; Cadaver; Chelating Agents; Deferoxamine; | 1999 |
Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Colony-Forming Units Assay; Deferoxamine; Drug Synergism; Er | 1999 |
Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Topics: Anemia; Chelating Agents; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Ferritins; Humans; I | 1999 |
Hypoxia promotes fibrogenesis in human renal fibroblasts.
Topics: Actins; Antimutagenic Agents; Cell Division; Cell Hypoxia; Cell Size; Cell Survival; Cells, Cultured | 2000 |
Possible mechanisms underlying potentiating effects of iron chelators in hematopoietic response to erythropoietin.
Topics: Anemia; Deferoxamine; Drug Synergism; Erythropoietin; Hematopoiesis; Humans; Kidney Failure, Chronic | 1992 |
Assessment of renal osteodystrophy in hemodialysis patients.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Aluminum; Biopsy; Calcium; Chronic Kidney Disease-Mine | 1992 |
[Dialysis bone disease associated with other factors].
Topics: Aluminum; Amyloidosis; Bone Diseases, Metabolic; Calcium Carbonate; Deferoxamine; Humans; Iron; Kidn | 1992 |
[Dialysis encephalopathy].
Topics: Anticonvulsants; Apraxias; Deferoxamine; Dementia; Electroencephalography; Humans; Kidney Failure, C | 1992 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Anemia; Bone Diseases, Metabolic; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failu | 1992 |
Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine.
Topics: Adult; Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Sucralfate | 1992 |
[Ototoxicity of deferoxamine].
Topics: Adult; Audiometry; Audiometry, Pure-Tone; Deferoxamine; Evoked Potentials, Auditory, Brain Stem; Fem | 1992 |
Aluminum toxicity.
Topics: Aluminum; Anemia; Animals; Deferoxamine; Dementia; Disease Models, Animal; Humans; Kidney Failure, C | 1991 |
Serum bactericidal activity for Yersinia enterocolitica in hemodialysis patients: effects of iron overload and deferoxamine.
Topics: Adult; Aged; Blood Bactericidal Activity; Deferoxamine; Female; Ferritins; Humans; Iron; Kidney Fail | 1992 |
[Speech apraxia in dialysis-associated aluminum encephalopathy].
Topics: Aluminum; Apraxias; Chelation Therapy; Deferoxamine; Follow-Up Studies; Humans; Kidney Failure, Chro | 1991 |
[Severe Yersinia enterocolitica infections in kidney failure patients under dialysis].
Topics: Adolescent; Adult; Deferoxamine; Female; Humans; Immune Tolerance; Iron; Kidney Failure, Chronic; Ma | 1991 |
Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
Topics: Adult; Aluminum; Chelation Therapy; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Osteomala | 1991 |
Aluminium determination in the skin of patients with and without end-stage renal failure.
Topics: Adult; Aged; Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ren | 1991 |
Erythropoietin and improvement in the erythropoiesis of chronic hemodialysis patients treated with desferrioxamine.
Topics: Deferoxamine; Erythropoiesis; Erythropoietin; Hemoglobins; Humans; Kidney Failure, Chronic; Renal Di | 1991 |
[The causes of aluminum cumulation and poisoning in patients with chronic kidney failure treated by hemodialysis on a regular program and the possibilities for therapy].
Topics: Aluminum; Aluminum Hydroxide; Calcium Carbonate; Deferoxamine; Hemodialysis Solutions; Hemofiltratio | 1991 |
Case management of the anemic patient epoetin alfa: focus on aluminum management.
Topics: Adult; Aged; Aluminum; Anemia; Deferoxamine; Erythropoietin; Female; Humans; Kidney Failure, Chronic | 1991 |
Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
Topics: Adult; Aluminum Hydroxide; Anemia, Hypochromic; Blood Transfusion; Deferoxamine; Female; Humans; Iro | 1990 |
Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
Topics: Adult; Aged; Aluminum; Chelation Therapy; Deferoxamine; Erythrocytes; Humans; Infusions, Intravenous | 1990 |
Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
Topics: Deferoxamine; Dialysis Solutions; Hemosiderosis; Humans; Iron; Kidney Failure, Chronic; Long-Term Ca | 1990 |
What treatment would you advise for a 1-year-old child with chronic renal failure who has been on aluminum hydroxide as a phosphate binder for 6 months and then develops epilepsy and is found to have a grossly raised plasma aluminum concentration?
Topics: Aluminum; Aluminum Hydroxide; Deferoxamine; Epilepsy; Humans; Infant; Kidney Failure, Chronic | 1990 |
The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment.
Topics: Aluminum; Anemia; Biological Availability; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Hum | 1990 |
Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine.
Topics: Aged; Aluminum; Citrates; Citric Acid; Deferoxamine; Drug Interactions; Gallium Radioisotopes; Human | 1990 |
Prospective evaluation of aluminum loading from formula in infants with uremia.
Topics: Aluminum; Bone and Bones; Deferoxamine; Dialysis Solutions; Follow-Up Studies; Histocytochemistry; H | 1990 |
Deferoxamine for aluminum toxicity in dialysis patients.
Topics: Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic | 1990 |
Cerebrospinal fluid aluminum levels following deferoxamine.
Topics: Adult; Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Kidney Trans | 1990 |
Silicon measurement in serum and urine by direct current plasma emission spectrometry.
Topics: Aluminum; Calcium; Creatine; Deferoxamine; Diet; Dose-Response Relationship, Drug; Humans; Kidney Ca | 1990 |
Trace elements and complications in patients undergoing chronic hemodialysis.
Topics: Aluminum; Anemia; Deferoxamine; Female; Hematocrit; Hemoglobins; Humans; Kidney Failure, Chronic; Ma | 1990 |
[Evaluation of thrombus scintigraphy using 67Ga-deferoxamine-dialdehydestarch-fibrinogen in patients with internal A-V shunt].
Topics: Adolescent; Adult; Arteriovenous Shunt, Surgical; Deferoxamine; Female; Fibrinogen; Gallium Radioiso | 1990 |
Bone histologic response to deferoxamine in aluminum-related bone disease.
Topics: Aluminum; Bone and Bones; Bone Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male | 1987 |
Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
Topics: Aluminum; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Di | 1989 |
Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis.
Topics: Aluminum; Anemia; Deferoxamine; Hematopoiesis; Hemoglobins; Humans; Kidney Failure, Chronic; Prospec | 1989 |
Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.
Topics: Adolescent; Deferoxamine; Glomerulonephritis, Membranous; Humans; Kidney Failure, Chronic; Male; Muc | 1989 |
Plasma aluminum levels (unstimulated and stimulated): clinical and biochemical findings in 185 patients undergoing chronic hemodialysis for 4 to 95 months.
Topics: Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Osteomalacia; Re | 1989 |
Iron status in patients receiving erythropoietin for dialysis-associated anemia.
Topics: Anemia; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failure, Chronic; Recombinant Proteins; R | 1989 |
[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine].
Topics: Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Rena | 1989 |
Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
Topics: Adolescent; Biomarkers; Deferoxamine; Female; Ferritins; Hemolytic-Uremic Syndrome; Humans; Infusion | 1989 |
Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
Topics: Aluminum; Bone and Bones; Bone Diseases; Calcium; Deferoxamine; Diabetic Nephropathies; Female; Huma | 1989 |
Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Topics: Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Macular Edema; Middle Aged; Optic N | 1989 |
Deferoxamine does not increase the risk for bacteremia in hemodialysis patients.
Topics: Adolescent; Adult; Aged; Child; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle | 1989 |
[Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
Topics: Adult; Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Osteomala | 1986 |
The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.
Topics: Aluminum; Animals; Bone Diseases; Deferoxamine; Disease Models, Animal; Kidney Failure, Chronic; Mal | 1988 |
Improvement of anaemia with desferrioxamine in haemodialysis patients.
Topics: Adult; Aluminum; Anemia; Blood Transfusion; Deferoxamine; Female; Hematocrit; Hemosiderosis; Humans; | 1987 |
Grand mal fitting in a patient on regular haemodialysis treatment and receiving desferrioxamine therapy.
Topics: Aluminum Hydroxide; Deferoxamine; Epilepsy, Tonic-Clonic; Female; Humans; Kidney Failure, Chronic; M | 1988 |
Treatment and histological healing of aluminum-related osteomalacia.
Topics: Adult; Aluminum; Calcium; Deferoxamine; Female; Hemodialysis Solutions; Humans; Hyperparathyroidism, | 1988 |
[Pigmentary changes of the retina in dialysis patients treated with deferoxamine].
Topics: Adult; Aged; Deferoxamine; Electrooculography; Electroretinography; Evoked Potentials, Visual; Human | 1988 |
Desferrioxamine-induced acute neurosensorial deafness.
Topics: Acute Disease; Adult; Deafness; Deferoxamine; Female; Humans; Kidney Failure, Chronic | 1988 |
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
Topics: Acute Disease; Adult; Aged; Deferoxamine; Female; Hearing Loss; Hearing Loss, Bilateral; Hearing Los | 1988 |
Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.
Topics: Aged; Aged, 80 and over; Aluminum; Chelating Agents; Deferoxamine; Humans; Iron; Kidney Failure, Chr | 1988 |
Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
Topics: Adult; Aluminum; Bone Diseases; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Mal | 1988 |
Toxic effects of aluminum in end-stage renal disease: discussion of a case.
Topics: Aluminum; Bone Diseases, Metabolic; Brain Diseases; Deferoxamine; Female; Hemodialysis, Home; Humans | 1988 |
Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
Topics: Adult; Aluminum; Deferoxamine; Female; Humans; Iron; Kidney Failure, Chronic; Male; Microchemistry; | 1987 |
Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
Topics: Aged; Bacterial Infections; Deferoxamine; Female; Hemosiderosis; Humans; Kidney Failure, Chronic; Ma | 1987 |
Role of desferrioxamine in the treatment of dialysis encephalopathy.
Topics: Adult; Aged; Aluminum; Brain Diseases; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; | 1986 |
Changes in bone histology after treatment with desferrioxamine.
Topics: Adolescent; Adult; Aluminum; Bone and Bones; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Mi | 1986 |
Aluminum intoxication of bone in renal failure--fact or fiction?
Topics: Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Osteomalacia; Renal Dialysis | 1986 |
Clinical and biochemical features of aluminum-related bone disease.
Topics: Adolescent; Adult; Aged; Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Midd | 1986 |
Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
Topics: Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Osteomalacia; Parathyroid Hormone; Renal Di | 1986 |
[Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
Topics: Aged; Aluminum; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Retinitis Pigme | 1987 |
Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
Topics: Adolescent; Aluminum; Bone and Bones; Child; Child, Preschool; Deferoxamine; Female; Humans; Kidney | 1987 |
The response of the normochromic normocytic anaemia of chronic renal failure to desferrioxamine.
Topics: Adult; Aged; Aluminum; Anemia; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Femal | 1987 |
[Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
Topics: Adult; Aluminum; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Female; Humans; Kid | 1987 |
Estimation of aluminoxamine and ferrioxamine in plasma by high performance liquid chromatography.
Topics: Aluminum; Chromatography, High Pressure Liquid; Deferoxamine; Ferric Compounds; Humans; Iron; Kidney | 1986 |
Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
Topics: Aluminum; Anemia, Hypochromic; Chelating Agents; Deferoxamine; Humans; Infant; Kidney Failure, Chron | 1986 |
Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
Topics: Aluminum; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Middle Aged; Myoclonus; R | 1986 |
Copper removal from renal patients using desferrioxamine chelation to reduce aluminium overload.
Topics: Aluminum; Bone and Bones; Bone Marrow; Copper; Deferoxamine; Humans; Kidney Failure, Chronic; Renal | 1986 |
Quantification of desferrioxamine in blood plasma by inductively coupled plasma atomic emission spectrometry.
Topics: Colorimetry; Deferoxamine; Humans; Indicators and Reagents; Kidney Failure, Chronic; Quality Control | 1987 |
[Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
Topics: Aluminum; Deferoxamine; Humans; Iron; Kidney Failure, Chronic; Renal Dialysis | 1986 |
Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
Topics: Adult; Aluminum; Anemia; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Erythrocyte | 1987 |
Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Feces; Female; Ferritins; Humans; Iron; Kidney F | 1985 |
Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
Topics: Adult; Aluminum; Deferoxamine; Electroencephalography; Female; Humans; Infusions, Parenteral; Kidney | 1985 |
Desferrioxamine in the treatment of aluminum overload.
Topics: Aluminum; Deferoxamine; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Kidney Failure, C | 1985 |
Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
Topics: Aluminum; Anemia; Child; Deferoxamine; Epilepsies, Myoclonic; Humans; Kidney Failure, Chronic; Male; | 1985 |
Elevated bone aluminum content in dialysis patients without osteomalacia.
Topics: Adult; Aluminum; Biopsy; Bone and Bones; Deferoxamine; Glomerulonephritis; Histocytochemistry; Human | 1985 |
[Successful treatment of progressive dialysis encephalopathy. Case report].
Topics: Aluminum; Deferoxamine; Dementia; Electroencephalography; Evoked Potentials; Female; Humans; Kidney | 1985 |
Thrombocytopenia associated with intravenous desferrioxamine.
Topics: Aluminum; Deferoxamine; Humans; Hypotension; Injections, Intravenous; Kidney Failure, Chronic; Male; | 1985 |
[Studies on evaluation of iron depots in terminal kidney failure].
Topics: Deferoxamine; Humans; Iron; Kidney Failure, Chronic; Methods; Renal Dialysis; Transferrin | 1973 |